Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.

Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Sun X, Berliner AJ, Schulze A, Zhao M, Schmelter T, Schmidt-Ott U, Zhang X, Morgan-Warren P, Hasanbasic Z, Vitti R, Chu KW, Reed K, Bhore R, Cheng Y, Bai Z, Hirshberg B, Yancopoulos GD, Wong TY, PULSAR Investigators

Open source

DOI: 10.1016/j.ophtha.2025.08.022
Published: 2026 Jan
Container: Ophthalmology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ophtha.2025.08.022,
  title = {Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.},
  author = {Korobelnik JF and Lanzetta P and Leal S and Holz FG and Clark WL and Eichenbaum D and Iida T and Sun X and Berliner AJ and Schulze A and Zhao M and Schmelter T and Schmidt-Ott U and Zhang X and Morgan-Warren P and Hasanbasic Z and Vitti R and Chu KW and Reed K and Bhore R and Cheng Y and Bai Z and Hirshberg B and Yancopoulos GD and Wong TY and PULSAR Investigators},
  year = {2026},
  journal = {Ophthalmology},
  doi = {10.1016/j.ophtha.2025.08.022},
  url = {https://doi.org/10.1016/j.ophtha.2025.08.022}
}

RIS

TY  - JOUR
TI  - Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.
AU  - Korobelnik JF
AU  - Lanzetta P
AU  - Leal S
AU  - Holz FG
AU  - Clark WL
AU  - Eichenbaum D
AU  - Iida T
AU  - Sun X
AU  - Berliner AJ
AU  - Schulze A
AU  - Zhao M
AU  - Schmelter T
AU  - Schmidt-Ott U
AU  - Zhang X
AU  - Morgan-Warren P
AU  - Hasanbasic Z
AU  - Vitti R
AU  - Chu KW
AU  - Reed K
AU  - Bhore R
AU  - Cheng Y
AU  - Bai Z
AU  - Hirshberg B
AU  - Yancopoulos GD
AU  - Wong TY
AU  - PULSAR Investigators
PY  - 2026
JO  - Ophthalmology
DO  - 10.1016/j.ophtha.2025.08.022
UR  - https://doi.org/10.1016/j.ophtha.2025.08.022
ER  -

APA

JF, K., P, L., S, L., FG, H., WL, C., D, E., T, I., X, S., AJ, B., A, S., M, Z., T, S., U, S., X, Z., P, M., Z, H., R, V., KW, C., K, R., R, B., Y, C., Z, B., B, H., GD, Y., TY, W., & Investigators, P. (2026). Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.. Ophthalmology. https://doi.org/10.1016/j.ophtha.2025.08.022

Source records

pubmed · retrieved 2026-09-26T10:34:15.918Z